InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,509.01
(
0.62%
)
US TECH 100
19,460.00
(
0.95%
)
Dow Jones
39,331.85
(
0.41%
)
Brent Oil
86.51
(
0.07%
)
Bitcoin
60,859.76
(
-1.88%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 353

Sunday, 09/16/2018 12:51:26 PM

Sunday, September 16, 2018 12:51:26 PM

Post# of 438
SESN develops fusion proteins.

Its lead program combines an antibody with a cytotoxin to treat bladder cancer

Top-line Ph3 data will be available H1/19

Ph2 data in this program delivered a ~40% Complete Response rate. Preliminary Ph3 data from 5/18 was similar

The primary concern for this program is AE. 4% are life threatening.

Cash runway extends into 2020.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up